- Uy, GL
- Costa, LJ
- Hari, PN
- Zhang, M-J
- Huang, J-X
- Anderson, KC
- Bredeson, CN
- Callander, NS
- Cornell, RF
- Perez, MAD
- Dispenzieri, A
- Freytes, CO
- Gale, RP
- Garfall, A
- Gertz, MA
- Gibson, J
- Hamadani, M
- Lazarus, HM
- Kalaycio, ME
- Kamble, RT
- Kharfan-Dabaja, MA
- Krishnan, AY
- Kumar, SK
- Kyle, RA
- Landau, HJ
- Lee, CH
- Maiolino, A
- Marks, DI
- Mark, TM
- Munker, R
- Nishihori, T
- Olsson, RF
- Ramanathan, M
- Rodriguez, TE
- Saad, AA
- Savani, BN
- Schiller, GJ
- Schouten, HC
- Schriber, JR
- Scott, E
- Seo, S
- Sharma, M
- Ganguly, S
- Stadtmauer, EA
- Tay, J
- To, LB
- Vesole, DH
- Vogl, DT
- Wagner, JL
- Wirk, B
- Wood, WA
- D'Souza, A
- et al.
In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (⩾0.5 × 10(9)/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (⩾20 × 10(9)/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.